Project Grant HT94252310660

This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...

This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at Yale University to investigate the role of the enzyme TENT2 in regulating microRNA-1 (miR-1) degradation in tumor endothelial cells (TECs) and its impact on tumor angiogenesis and progression in non-small cell lung cancer (NSCLC). The $430,684 award, which runs from July 2024 to June 2026, will support two specific aims: 1) determining the role of TENT2 in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $458,051 to Temple University to conduct research aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key products and services to be delivered under this 4-year award include: Investigating whether low levels of the nuclear structural protein LMNA contribute to the high levels of replication stress observed in SCLC cells, and whether this...

This Project Grant award of $248,999 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Washington University will leverage patient-specific induced pluripotent stem cell (iPSC)-derived cardiac pericytes and endothelial cells to elucidate the molecular and cellular basis of tyrosine kinase inhibitor-induced vascular toxicity (TKI-VT) and discover personalized therapies. The key objectives are to: Characterize sunitinib-induced cytotoxicity...

This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $136,266 to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research focused on therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation. The project aims to determine the mechanisms by which inactivation of the EED gene promotes the transformation from SCLC to lung adenocarcinoma (LUAD), as well as how RB1 inactivation mediates...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is supporting a research effort led by The Trustees of Columbia University in the City of New York to develop novel inhalable extracellular vesicles (exosomes) for enhanced delivery of interleukin-12 (IL12) to treat lung cancer. The $128,228 award, spanning July 1, 2025 to June 30, 2027, aims to engineer exosome-based RNA delivery platforms that can achieve high mRNA encapsulation, scalability,...

The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $566,523 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to identify interception targets in persistent lung premalignant lesions (PMls) that are at risk of progressing to lung cancer. The key objectives are to: 1) Identify interception targets in the persistence profile in clinical trial biopsies, 2) Determine effects of...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...